gl261 cell line  (Virotech Diagnostics GmbH)

Journal: Nature Communications

Article Title: Plasma-to-tumour tissue integrated proteomics using nano-omics for biomarker discovery in glioblastoma

doi: 10.1038/s41467-025-58252-0

Figure Lengend Snippet: a Overview of the in vivo study design enabling plasma and brain tissue proteomic profiling in GB tumour-bearing mice. A syngeneic GB murine model was established in C57BL/6 J female mice via intracranial injection of GL261 cells. Control mice underwent sham injection with saline. PEGylated liposome nanoparticles (NPs) were intravenously administered at days 7, 14, and 18 post-intracranial GL261 cell injection to allow protein corona formation. The corona-coated NPs were subsequently recovered from the blood circulation and purified to remove any unbound proteins. Brains were collected from control and tumour-bearing mice at all three-time points of investigation. Created in BioRender. Hadjidemetriou, M. (2025) https://BioRender.com/z49a544 . b Histological characterisation of GL261 tumours at day 7 (D7), day 14 (D14), and day 18 (D18) by haematoxylin and eosin (H&E) staining. c Quantification of the tumour volume in GB mice at days 7, 14, and 18 ( n = 9 biological replicates for D7 and D14, n = 8 biological replicates for D18; error bars indicate mean ± SEM; * p -value = 0.0409 between D7 and D14, **** p -value < 0.0001 between D7 and D18, **** p -value < 0.0001 between D14 and D18 by One-way ANOVA with Tukey’s multiple comparison test). Source data for Fig. 1c are provided as a Source Data file.

Article Snippet: The murine GL261 cell line was obtained from the Leibniz Institute DSMZ, Germany.

Techniques: In Vivo, Clinical Proteomics, Injection, Control, Saline, Purification, Staining, Comparison

Journal: Nature Communications

Article Title: Plasma-to-tumour tissue integrated proteomics using nano-omics for biomarker discovery in glioblastoma

doi: 10.1038/s41467-025-58252-0

Figure Lengend Snippet: a Schematic overview of the in vivo plasma proteomics workflow. Following the intracranial injection of GL261 glioma cells (for GB-bearing mice) or saline (for control mice), C57BL/6 J female mice were intravenously administrated liposome NPs at days 7, 14, and 18 post-tumour implantations. Blood-circulating NPs were subsequently recovered, and corona-coated NPs were purified prior to LC-MS/MS analysis. Created in BioRender. Hadjidemetriou, M. (2025) https://BioRender.com/g08d103 . b The total amount of protein adsorbed onto the surface of liposome NPs was quantified and expressed as protein binding value (μg of protein/μmol lipid). Error bars indicate mean ± SEM of n = 3 biological replicates (plasma pooled from n = 5 mice for each biological replicate; * p -value = 0.0414 between D7 GBM and D14 GBM; ** p -value = 0.009 between D7 GBM and D18 GBM; One-way ANOVA with Tukey’s multiple comparisons test between three-time points within the GB group; ** p -value = 0.0028 by Sidak’s multiple comparisons between the control and GB groups at D18 time point. c The Venn diagram illustrates the number of common and unique differentially abundant proteins (DAPs) identified at D7, D14, and D18 time points (proteins with a p -value < 0.05). Statistical comparisons of relative protein expressions between corona proteomes from tumour-bearing mice and control mice were conducted using Progenesis QI for proteomics software (v. 3.0; Nonlinear Dynamics). d Bar graph reports the number and percentage of upregulated and downregulated DAPs identified through the analysis of the protein coronas formed in GB and healthy control mice ( n = 3 biological replicates; pooled plasma from n = 5 mice per biological replicate). e Volcano plots display the relationship between fold change (shown in x -axis) and statistical significance (shown in y -axis) of the DAPs (with one-way ANOVA p -value < 0.05) at D7, D14 and D18 time points. The comprehensive lists of DAPs are provided in Supplementary Data − . Source data for Fig. 2b are provided as a Source Data file.

Article Snippet: The murine GL261 cell line was obtained from the Leibniz Institute DSMZ, Germany.

Techniques: In Vivo, Clinical Proteomics, Injection, Saline, Control, Purification, Liquid Chromatography with Mass Spectroscopy, Protein Binding, Software